Analysis Of Prognostic Factors Of High Grade Glioma Patients

Purpose:Malignant glioma is one of the most common and aggressive type of primary brain tumor with 5-year survival lower than 5%, 2-year mortality higher than 75% and median survival time only 15 months. Certain factors may influence the prognosis of patients with malignant glioma as gender, age, pathological pattern, radiotherapy technique, chemotherapy, tumor location, tumor resection and patients’ KPS after surgery. In this work we sought to evaluate whether these factors as above would influence the prognosis of patients with malignant glioma, as well as recognize the role Traditional Chinese Medicine played in treating malignant glioma.Material and method:Both OS(overall survival) and PFS(progress free survival) of 64 patients diagnosed with malignant glioma were retrospectively analyzed with the factors above by using the statistical method Kaplan-Meier, Long-rank and Cox.Results:Factors which can influence OS are tumor resection(P=0.004, P<0.05), radiotherapy technique(P=0.029, P<0.05), chemotherapy(P=0.023, P<0.05) and pathological pattern(P=0.000, P<0.05). By comparing 3 radiotherapy techniques we found that the OS of 3D-CRT, IMRT and TOMO are 12.2 months, 25.2 months and 27.4 months, respectively. Only the difference between IMRT and TOMO exerts no statistical variance.(P3D-CRT vs IMRT =0.009, P<0.05; P3D-CRT vs TOMO=0.001, P<0.05; PIMRT vs TOMO=0.406, P>0.05) Factors which can influence PFS are tumor resection(P=0.000, P<0.05), radiotherapy technique(P=0.037, P<0.05), chemotherapy(P=0.002, P<0.05) and pathological pattern(P=0.000, P<0.05). By comparing 3 radiotherapy techniques we found that the PFS of 3D-CRT, IMRT and TOMO are 7.4 months, 12.8 months and 17.4 months, respectively. All groups exerts statistical variance.(P3D-CRT vs IMRT =0.000, P<0.05; P3D-CRT vs TOMO=0.000, P<0.05; PIMRT vs TOMO=0.046, P>0.05)Conclusion:Patients who are diagnosed with anaplastic astrocytomas, receiving total removal surgery followed by helical radiotherapy with concurrent and concomitant temozolomide chemotherapy present better prognosis than patients who are diagnosed with glioblastoma multiforme, receiving partial removal surgery followed only by IMRT or 3D-CRT.